XSC-86933-05610
2 vaccinations
1 coded response
1 check-in
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 940 / CA
- Registered
- 2021-06-10
- Relationship
- Self
- Race
- Asian
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-05-20
Dose 1 — Pfizer-BioNTech
-
2021-06-10
Registered in v-safe
-
2021-06-10
Dose 2 — Pfizer-BioNTech
-
2021-06-11
Survey response — days 1–6 daily, dose 2MedDRA: Eye haemorrhage — Feeling: Good · Site: Pain · Fatigue or tirednessFree text: Blood vessel rupture in eyeMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-05-20 | Pfizer-BioNTech | |
| 2 | 2021-06-10 | Pfizer-BioNTech |
Free text
Release 9 — days 1–6 daily, dose 2
Systemic reaction (other): Blood vessel rupture in eye
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SRO | Eye haemorrhage | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release